Table 4 MSC thawing: pre and post-thaw MSC immunosuppressive properties
From: Clinical-scale expansion of mesenchymal stromal cells: a large banking experience
|  | (%) | Min. | Max. | Mean ± SD |
|---|---|---|---|---|
Day 0 | Recovery | 61 | 84 | 72.8 ± 10.4 |
Viability | 61 | 71 | 65.1 ± 4.4 | |
Immunosuppression | 5 | 5 | 5.0 ± 0.0 | |
Day 1 | Recovery | 21 | 54 | 41.8 ± 12.9 |
Viability | 86 | 91 | 88.8 ± 2.1 | |
Immunosuppression | 0 | 10 | 2.9 ± 4.1 | |
Day 2 | Recovery | 19 | 40 | 30.3 ± 11.3 |
Viability | 78 | 87 | 83.9 ± 4.0 | |
Immunosuppression | 4 | 19 | 10.3 ± 7.4 | |
Day 3 | Recovery | 21 | 36 | 26.8 ± 10.8 |
Viability | 74 | 97 | 85.5 ± 16.3 | |
Immunosuppression | 34 | 47 | 40.5 ± 8.6 | |
Day 4 | Recovery | 21 | 34 | 28.3 ± 6.5 |
Viability | 89 | 93 | 90.3 ± 2.3 | |
Immunosuppression | 40 | 43 | 41.8 ± 2.2 | |
Day 5 | Recovery | 31 | 42 | 36.3 ± 7.5 |
Viability | 85 | 91 | 88.0 ± 4.2 | |
Immunosuppression | 42 | 44 | 42.6 ± 1.3 |